Physician profile
Mark Hill
NPI 1366737819
$3,950.71
in general payments reported to CMS, 2019-2025
23 companies · $387 in 2025
The $387 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,117 · 2020: $59.22 · 2021: $275 · 2022: $391 · 2023: $298 · 2024: $425 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,109.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,665.43 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $369.51 | 2019-2025 | Cequa, Xelpros |
| Allergan, INC. | $357.49 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $276.58 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Regeneron Healthcare Solutions, INC. | $269.07 | 2019-2025 | Eylea Hd, Eylea |
| Alcon Vision LLC | $243.66 | 2019-2025 | Hydrus Microstent |
| Rxsight INC | $165.25 | 2021-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Novartis Pharmaceuticals Corporation | $70.62 | 2019-2023 | |
| Amgen INC. | $70.47 | 2024-2025 | Tepezza |
| Apellis Pharmaceuticals, INC. | $70.21 | 2023-2024 | Syfovre |
| Genentech USA, INC. | $54.55 | 2022-2024 | Vabysmo |
| Glaukos Corporation | $48.92 | 2019-2025 | Istent Infinite |
| Sight Sciences, INC. | $42.86 | 2022-2025 | Sion Surgical Instrument, Omni Surgical System |
| Heidelberg Engineering, INC. | $41.78 | 2023 | Spectralis |
| Abbvie INC. | $40.25 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $37.57 | 2021-2022 | |
| Astellas Pharma US INC | $26.29 | 2025 | Izervay |
| Dompe US, INC. | $22.09 | 2019 | |
| Thea Pharma INC. | $20.54 | 2024 | Iyuzeh |
| Ivantis, INC | $15.25 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.30 | 2021 | |
| Horizon Therapeutics Plc | $14.06 | 2023 | Tepezza |
| Optos, INC. | $13.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.